Histamine News and Research

RSS

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.

Presenilin-1 gene plays central role in development of neuronal histamine system

Researchers at University of Helsinki, Finland, have shown in a study conducted on zebrafish, that the presenilin-1 (psen1) gene associated with Alzheimer's disease functions as a central regulator for the development of the histamine system. Histamine system is also altered in patients suffering from Alzheimer's disease.

5 Feb 2013

Trial to evaluate whether zolpidem reduces suicidal thinking in depressed insomniacs

Researchers want to know whether a sleeping pill reduces suicidal thoughts in depressed patients with insomnia.

23 Jan 2013

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality.

21 Jan 2013

Itch-specific nerve cells in skin discovered by John Hopkins scientists

Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.

3 Jan 2013

Johns Hopkins scientists uncover itch-specific nerve cells in skin

3 Jan 2013

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Allergies common in ADHD, tic disorder patients

A significant number of people with attention deficit/hyperactivity disorder and tic disorder also have one or more allergic diseases such as asthma or atopic dermatitis, show study results.

23 Nov 2012

Scientists develop measures to prevent health problems associated with biogenic amines in wine

Biogenic amines may be one of the factors responsible for symptoms such as headaches, gastro-intestinal disorders, shortness of breath, fall in blood pressure, and even unconsciousness and cardiac arrhythmia in severe cases. Histamine, one of the best known members of this group, can cause serious physical problems. Biogenic amines can be produced in the body by natural metabolic activities but are also ingested in larger quantities with food.

8 Nov 2012

Seniors can play an important role in reducing risks associated with prescription medications

Common medication to treat insomnia, anxiety, itching or allergies can have a negative impact on memory or concentration in the elderly, according to Dr. Cara Tannenbaum, Research Chair at the Institut universitaire de g-riatrie de Montr-al (IUGM, Montreal Geriatric University Institute) and Associate Professor of Medicine and Pharmacy at the University of Montreal (UdeM).

6 Nov 2012

NJH researchers discover novel target for treatment of food allergies

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

2 Nov 2012

Researchers learn how E2-79 molecule destroys complexes that induce allergic responses

Researchers have learned how a man-made molecule destroys complexes that induce allergic responses - a discovery that could lead to the development of highly potent, rapidly acting interventions for a host of acute allergic reactions.

29 Oct 2012

UK acid-related disease trends revealed

The incidence of Barrett’s esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.

11 Oct 2012

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time.

24 Sep 2012

Tips to help minimize risks associated with acid reflux disease

While the overall death rates from several cancers such as breast and lung have gone down, there has been a meteoric rise in cases of esophageal cancer. Studies have shown that from 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from four to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.

17 Jul 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012

Mallinckrodt, Horizon enter co-promotion agreement for DUEXIS

Mallinckrodt, the Pharmaceuticals business of Covidien, today announced that it has entered into a co-promotion agreement with Horizon Pharma, Inc. to promote DUEXIS (ibuprofen and famotidine).

18 Jun 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

Latest AAN/AHS guidelines can help prevent migraine attacks

The latest American Academy of Neurology/American Headache Society Guidelines released this week outline evidence-based and effective treatments that can prevent migraine attacks and lessen their severity.

26 Apr 2012

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.

24 Apr 2012